Cross-reactivity studies and predictive modeling of “Bath Salts” and other amphetamine-type stimulants with amphetamine screening immunoassays

References

• Peters FT, Martinez-Ramirez JA. Analytical toxicology of emerging drugs of abuse. Ther Drug Monit 2010; 32:532–539.
   PubMed Web of Science ®Google Scholar
• Hill SL, Thomas SH. Clinical toxicology of newer recreational drugs. Clin Toxicol (Phila) 2011; 49:705–719.
   PubMed Web of Science ®Google Scholar
• Ross EA, Watson M, Goldberger B. “Bath salts” intoxication. N Engl J Med 2011; 365:967–968.
   PubMed Web of Science ®Google Scholar
• Winder GS, Stern N, Hosanagar A. Are “Bath Salts” the next generation of stimulant abuse? J Subst Abuse Treat 2012.
   PubMed Web of Science ®Google Scholar
• Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: temporary placement of synthetic cathinones in Schedule I. Final Order. Fed Regist 2011; 76: 65371–65375.
   PubMedGoogle Scholar
• Administration USDE. Congress agrees to add 26 synthetic drugs to Controlled Substances Act. 2012 [updated 2012; cited]; Available from: http://www.justice.gov/dea/pubs/pressrel/pr061912.html.
   Google Scholar
• Apollonio LG, Whittall IR, Pianca DJ, Kyd JM, Maher WA. Matrix effect and cross-reactivity of select amphetamine-type substances, designer analogues, and putrefactive amines using the Bio-Quant direct ELISA presumptive assays for amphetamine and methamphetamine. J Anal Toxicol 2007; 31:208–213.
   PubMed Web of Science ®Google Scholar
• Kerrigan S, Mellon MB, Banuelos S, Arndt C. Evaluation of commercial enzyme-linked immunosorbent assays to identify psychedelic phenethylamines. J Anal Toxicol 2011; 35:444–451.
   PubMed Web of Science ®Google Scholar
• Nakanishi K, Miki A, Zaitsu K, Kamata H, Shima N, Kamata T, . Cross-reactivities of various phenethylamine-type designer drugs to immunoassays for amphetamines, with special attention to the evaluation of the one-step urine drug test Instant-View, and the Emit(R) assays for use in drug enforcement. Forensic Sci Int 2012; 217:174–181.
   PubMed Web of Science ®Google Scholar
• Ewald AH, Peters FT, Weise M, Maurer HH. Studies on the metabolism and toxicological detection of the designer drug 4-methylthioamphetamine (4-MTA) in human urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 824:123–131.
   PubMed Web of Science ®Google Scholar
• Kamata HT, Shima N, Zaitsu K, Kamata T, Miki A, Nishikawa M, . Metabolism of the recently encountered designer drug, methylone, in humans and rats. Xenobiotica 2006; 36:709–723.
   PubMed Web of Science ®Google Scholar
• Meyer MR, Wilhelm J, Peters FT, Maurer HH. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem 2010; 397:1225–1233.
   PubMed Web of Science ®Google Scholar
• Staack RF, Maurer HH. Metabolism of designer drugs of abuse. Curr Drug Metab 2005; 6:259–274.
   PubMed Web of Science ®Google Scholar
• Zaitsu K, Katagi M, Kamata T, Kamata H, Shima N, Tsuchihashi H, . Determination of a newly encountered designer drug “p-methoxyethylamphetamine” and its metabolites in human urine and blood. Forensic Sci Int 2008; 177:77–84.
   PubMed Web of Science ®Google Scholar
• Krasowski MD, Pizon AF, Siam MG, Giannoutsos S, Iyer M, Ekins S. Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine. BMC Emerg Med 2009; 9:5.
   PubMedGoogle Scholar
• Krasowski MD, Siam MG, Iyer M, Pizon AF, Giannoutsos S, Ekins S. Chemoinformatic methods for predicting interference in drug of abuse/toxicology immunoassays. Clin Chem 2009; 55:1203–1213.
   PubMed Web of Science ®Google Scholar
• Krasowski MD, Siam MG, Iyer M, Ekins S. Molecular similarity methods for predicting cross-reactivity with therapeutic drug monitoring immunoassays. Ther Drug Monit 2009; 31:337–344.
   PubMed Web of Science ®Google Scholar
• Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL. Global mapping of pharmacological space. Nat Biotechnol 2006; 24:805–815.
   PubMed Web of Science ®Google Scholar
• Willett P. Similarity-based approaches to virtual screening. Biochem Soc Trans 2003; 31:603–606.
   PubMed Web of Science ®Google Scholar
• Bissantz C, Folkers G, Rognan D. Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. J Med Chem 2000; 43:4759–4767.
   PubMed Web of Science ®Google Scholar
• Charifson PS, Corkery JJ, Murcko MA, Walters WP. Consensus scoring: a method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J Med Chem 1999; 42:5100–5109.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Muegge I. Scaffold hopping through virtual screening using 2D and 3D similarity descriptors: ranking, voting, and consensus scoring. J Med Chem 2006; 49:1536–1548.
   PubMed Web of Science ®Google Scholar
• Wang QC, Shang Y, Xu D. Improving a consensus approach for protein structure selection by removing redundancy. IEEE/ACM Trans Comput Biol Bioinform 2011; 8:1708–1715.
   PubMed Web of Science ®Google Scholar
• Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery: applications to targets and beyond. Br J Pharmacol 2007; 152:21–37.
   PubMed Web of Science ®Google Scholar
• Li J, Ehler T, Sutter J, Varma-O’Brien S, Kirchmair J. CAESAR: a new conformer generation algorithm based on recursive buildup and local rotational symmetry consideration. J Chem Inf Model 2007; 47:1923–1932.
   PubMed Web of Science ®Google Scholar
• Astorga B, Ekins S, Morales M, Wright SH. Molecular determinants of ligand selectivity for the human multidrug and toxin extruder proteins MATE1 and MATE2-K. J Pharmacol Exp Ther 2012; 341:743–755.
   PubMed Web of Science ®Google Scholar
• Diao L, Ekins S, Polli JE. Quantitative structure activity relationship for inhibition of human organic cation/carnitine transporter. Mol Pharm 2010; 7:2120–2131.
   PubMed Web of Science ®Google Scholar
• Fidler AE, Holland PT, Reschly EJ, Ekins S, Krasowski MD. Activation of a tunicate (Ciona intestinalis) xenobiotic receptor orthologue by both natural toxins and synthetic toxicants. Toxicon 2011; 59:365–372.
   PubMed Web of Science ®Google Scholar
• Celikel R, Peterson EC, Owens SM, Varughese KI. Crystal structures of a therapeutic single chain antibody in complex with two drugs of abuse-Methamphetamine and 3,4-methylenedioxymethamphetamine. Protein Sci 2009; 18:2336–2345.
   PubMed Web of Science ®Google Scholar
• Dickson AJ, Vorce SP, Holler JM, Lyons TP. Detection of 1-benzylpiperazine, 1-(3-trifluoromethylphenyl)-piperazine, and 1-(3-chlorophenyl)-piperazine in 3,4-methylenedioxymethamphetamine-positive urine samples. J Anal Toxicol 2008; 34: 464–469.
   Web of Science ®Google Scholar
• Dickson AJ, Vorce SP, Levine B, Past MR. Multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephedrone) and heroin. J Anal Toxicol 2010; 34:162–168.
   PubMed Web of Science ®Google Scholar
• Soares ME, Carvalho M, Carmo H, Remiao F, Carvalho F, Bastos ML. Simultaneous determination of amphetamine derivatives in human urine after SPE extraction and HPLC-UV analysis. Biomed Chromatogr 2004; 18:125–131.
   PubMed Web of Science ®Google Scholar
• Shulgin A, Shulgin A. PIHKAL: A Chemical Love Story. Berkeley, CA: Transform Press; 1991.
   Google Scholar
• Shulgin A, Shulgin A. TIHKAL: The Continuation. Berkeley, CA: Transform Press; 1997.
   Google Scholar
• Christophersen AS. Amphetamine designer drugs – an overview and epidemiology. Toxicol Lett 2000; 112–113:127–131.
   PubMed Web of Science ®Google Scholar
• Nichols DE. Hallucinogens. Pharmacol Ther 2004; 101:131–181.
   PubMed Web of Science ®Google Scholar
• Kortagere S, Krasowski MD, Ekins S. The importance of discerning shape in molecular pharmacology. Trends Pharmacol Sci 2009; 30:138–147.
   PubMed Web of Science ®Google Scholar
• Kristam R, Gillet VJ, Lewis RA, Thorner D. Comparison of conformational analysis techniques to generate pharmacophore hypotheses using catalyst. J Chem Inf Model 2005; 45:461–476.
   PubMed Web of Science ®Google Scholar
• Larsen NA, Zhou B, Heine A, Wirsching P, Janda KD, Wilson IA. Crystal structure of a cocaine-binding antibody. J Mol Biol 2001; 311:9–15.
   PubMed Web of Science ®Google Scholar
• Pozharski E, Moulin A, Hewagama A, Shanafelt AB, Petsko GA, Ringe D. Diversity in hapten recognition: structural study of an anti-cocaine M82G2. J Mol Biol 2005; 349:570–582.
   PubMed Web of Science ®Google Scholar
• Pozharski E, Wilson MA, Hewagama A, Shanafelt AB, Petsko G, Ringe D. Anchoring a cationic ligand: the structure of the Fab fragment of the anti-morphine antibody 9B1 and its complex with morphine. J Mol Biol 2004; 337:691–697.
   PubMed Web of Science ®Google Scholar
• Lim K, Owens SM, Arnold L, Sacchettini JC, Linthicum DS. Crystal structure of monoclonal 6B5 Fab complexed with phencyclidine. J Biol Chem 1998; 273:28576–28582.
   PubMed Web of Science ®Google Scholar
• Monnet C, Bettsworth F, Stura EA, Le Du MH, Menez R, Derrien L, . Highly specific anti-estradiol antibodies: structural characterisation and binding diversity. J Mol Biol. 2002; 315: 699–712.
   PubMed Web of Science ®Google Scholar